Tags

Type your tag names separated by a space and hit enter

Seizures in patients receiving concomitant antimuscarinics and acetylcholinesterase inhibitor.
Pharmacotherapy. 1998 Sep-Oct; 18(5):1129-32.P

Abstract

Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor. In both patients seizures were associated with discontinuation of short-term agents with high antimuscarinic properties. Hence, abrupt discontinuation of antimuscarinics or anticholinergics with high antimuscarinic properties in patients receiving long-term acetylcholinesterase inhibition therapy may be associated with a reduction of seizure threshold. With increasing administration of acetylcholinesterase inhibitors for patients with Alzheimer's disease, practitioners should be aware of the potential for drug-drug interactions and other complications. In general, it is good medical practice to avoid concomitant administration with centrally acting anticholinergic agents.

Authors+Show Affiliations

Drug Product Evaluation Unit, College of Pharmacy, University of Kentucky, Lexington, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9758325

Citation

Piecoro, L T., et al. "Seizures in Patients Receiving Concomitant Antimuscarinics and Acetylcholinesterase Inhibitor." Pharmacotherapy, vol. 18, no. 5, 1998, pp. 1129-32.
Piecoro LT, Wermeling DP, Schmitt FA, et al. Seizures in patients receiving concomitant antimuscarinics and acetylcholinesterase inhibitor. Pharmacotherapy. 1998;18(5):1129-32.
Piecoro, L. T., Wermeling, D. P., Schmitt, F. A., & Ashford, J. W. (1998). Seizures in patients receiving concomitant antimuscarinics and acetylcholinesterase inhibitor. Pharmacotherapy, 18(5), 1129-32.
Piecoro LT, et al. Seizures in Patients Receiving Concomitant Antimuscarinics and Acetylcholinesterase Inhibitor. Pharmacotherapy. 1998 Sep-Oct;18(5):1129-32. PubMed PMID: 9758325.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Seizures in patients receiving concomitant antimuscarinics and acetylcholinesterase inhibitor. AU - Piecoro,L T, AU - Wermeling,D P, AU - Schmitt,F A, AU - Ashford,J W, PY - 1998/10/3/pubmed PY - 1998/10/3/medline PY - 1998/10/3/entrez SP - 1129 EP - 32 JF - Pharmacotherapy JO - Pharmacotherapy VL - 18 IS - 5 N2 - Seizures occurred in two patients with probable Alzheimer's disease who were receiving long-term treatment with metrifonate, an irreversible acetylcholinesterase inhibitor. In both patients seizures were associated with discontinuation of short-term agents with high antimuscarinic properties. Hence, abrupt discontinuation of antimuscarinics or anticholinergics with high antimuscarinic properties in patients receiving long-term acetylcholinesterase inhibition therapy may be associated with a reduction of seizure threshold. With increasing administration of acetylcholinesterase inhibitors for patients with Alzheimer's disease, practitioners should be aware of the potential for drug-drug interactions and other complications. In general, it is good medical practice to avoid concomitant administration with centrally acting anticholinergic agents. SN - 0277-0008 UR - https://www.unboundmedicine.com/medline/citation/9758325/Seizures_in_patients_receiving_concomitant_antimuscarinics_and_acetylcholinesterase_inhibitor_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0277-0008&date=1998&volume=18&issue=5&spage=1129 DB - PRIME DP - Unbound Medicine ER -